This percentage may increase by screening nephrolithiasis patients for mutations in USP2 or in clock genes controlling its expression such as ARNTL (BMAL1) and CLOCK and their binding sites in the promoter of USP2. The gene discussed is USP2; the disease is nephrolithiasis.